Table 2. POD 1 Cut-Off-Levels (PDR & R15), Patient demographics, outcome- and laboratory parameters.
| Parameter | Collective (N = 137)/ Missing values (N = 11) | ||||||
|---|---|---|---|---|---|---|---|
| POD 1 | PDR ≥ 10%/min. | PDR < 10%/min. | P—value | R15 ≤ 20% | R15 >20% | P—value | |
| N = / Median (Range/ %) | N = / Median (Range/ %) | N = / Median (Range/ %) | |||||
| Age (years) | 62 (22–89) | 62 (22–89) | 62 (39–81) | 0.64 | 62 (22–89) | 63 (39–81) | 0.38 |
| Sex | |||||||
| Male | 80 (63.5%) | 74 (64.3%) | 6 (54.5%) | 0.52 | 72 (64.3%) | 8 (57.1%) | 0.60 |
| Female | 46 (36.5) | 41 (35.7%) | 5 (45.5%) | 40 (35.7%) | 6 (42.9%) | ||
| Neoplastic entity | |||||||
| mCRC | 54 (42.9%) | 52 (45.2%) | 2 (18.2%) | 0.25 | 51 (45.5%) | 3 (21.4%) | 0.21 |
| HCC | 26 (20.6%) | 21 (18.3%) | 5 (45.5%) | 20 (17.9%) | 6 (42.9%) | ||
| CCC | 21 (16.7%) | 19 (16.5%) | 2 (18.2%) | 18 (16.1%) | 3 (21.4%) | ||
| Non neoplastic Adenomas or Haemangiomas | 13 (10.3%) | 12 (10.4%) | 1 (9.1%) | 12 (10.7) | 1 (7.1%) | ||
| Others | 12 (9.5%) | 11 (9.6%) | 1 (9.1%) | 11 (9.8%) | 1 (7.1%) | ||
| Preoperative CTx | |||||||
| Yes | 48 (38.1%) | 46 (40.0%) | 2 (18.2%) | 0.15 | 45 (40.2%) | 3 (21.4%) | 0.17 |
| Hepatic resection | |||||||
| Major | 55 (43.7%) | 45 (39.1%) | 10 (90.9%) | 0.001 | 42 (37.5%) | 13 (92.9%) | 0.001 |
| Minor | 71 (56.3%) | 70 (60.9%) | 1 (9.1%) | 70 (62.5%) | 1 (7.1%) | ||
| LD | |||||||
| Yes | 10 (7.9%) | 5 (4.3%) | 5 (45.5%) | 0.001 | 4 (3.6%) | 6 (42.9%) | 0.001 |
| Child Pugh Score/ Missing values (N = 29) | |||||||
| A | 99 (91.7%) | 91 (93.8%) | 8 (72.2%) | 0.016 | 89 (93.7%) | 10 (76.9%) | 0.040 |
| B | 9 (8.3%) | 6 (6.2%) | 3 (27.3%) | 6 (6.3%) | 3 (23.1%) | ||
| MELD Score | 6 (6–16) | 6 (6–16) | 6 (6–15) | 0.77 | 6 (6–16) | 6 (6–15) | 0.91 |
| Postoperative Parameters | |||||||
| PDR%/min. | 20.1 (6.8–72.3) | 21.30 (10.1–72.3) | 8.9 (6.8–9.8) | 21.7 (11.0–72.3) | 9.5 (6.8–14.3) | ||
| R15% | 5.0 (0.0–36.1) | 4.20 (0.0 22.7) | 26.30 (23.0–36.1) | 4.1 (0.0–19.2) | 24.0 (20.7–36.1) | ||
| SB mg/dl | 1.2 (0.4–8.2) | 1.13 (0.4–6.9) | 2.9 (1.0–8.2) | 0.001 | 1.13 (0.4–6.9) | 2.7 (1.0–8.2) | 0.001 |
| PT% a | 56.0 (29.0–91.0) | 57.0 (30.0–90.0) | 44.0 (29.0–91.0) | 0.003 | 57.0 (30.0–90.0) | 45.5 (29.0–91.0) | 0.006 |
| ALP U/l | 60.0 (31.0–335.0) | 60.0 (31.0–286.0) | 56.0 (40.0–335.0) | 0.94 | 60.0 (31.0–286.0) | 63.5 (40.0–335.0) | 0.77 |
| GGT U/l | 59.0 (6.0–431.0) | 58.0 (6.0–335.0) | 62.0 (22.0–431.0) | 0.47 | 58.0 (6.0–335.0) | 67.5 (22.0–431.0) | 0.31 |
| AST U/l | 342.5 (56.0–4298.0) | 341.0 (56.0–2093.0) | 419.0 (269.0–4298.0) | 0.16 | 339.5 (56.0–2093.0) | 415.0 (159.0–4298.0) | 0.18 |
| ALT U/l | 341.0 (70.0–3409.0) | 339.0 (70.0–1769.0) | 363.0 (164.0–3409.0) | 0.56 | 340.0 (70.0–1769.0) | 360.5 (158.0–3409.0) | 0.70 |
| Albumin g/l | 29.8 (19.6–40.3) | 29.9 (19.6–40.3) | 28.9 (20.0–34.2) | 0.15 | 30.0 (19.6–40.3) | 27.8 (20.0–34.2) | 0.026 |
| Platelets (x10^3/μl) | 176.0 (70.0–444.0) | 175.5 (70.0–444.0) | 176.0 (77.0–294.0) | 0.85 | 176.0 (70.0–444.0) | 175.5 (77.0–294.0) | 0.72 |
ALP, alkaline phosphatase; ALT, alanine amino transferase; AST, aspartate amino transferase; CCC, cholangiocellular carcinoma; CTx, chemo therapy; GGT, gamma glutamyl transferase; HCC, hepatocellular carcinoma; LD, liver dysfunction; mCRC, metastatic colorectal cancer; PDR, plasma diffusion rate; POD, postoperative day; PT, prothrombin time; R15, retention rate at 15 minutes; SB, serum bilirubin
a PT is expressed in relation to the coagulation time of a healthy person (i.e. Quick). Accordingly, it is illustrated in percentage.